Program Overview
Hair follicle regeneration addresses a persistent clinical need: androgenetic alopecia and related conditions where conventional transplantation is limited by donor follicle supply and existing pharmacotherapy offers incomplete results.
Orion Biotech's program centers on autologous follicle-derived cells—including dermal papilla and dermal sheath populations—expanded under controlled culture conditions and evaluated for hair-inductive potential in translational models.
Technical Approach
The workflow encompasses follicle sampling, cell isolation, expansion, 3D aggregate formation, and transplantation research. Early work established spherical dermal papilla structures in vitro and defined critical variables for survival, inductivity, and integration after transplantation.
Current research emphasizes boundary conditions for cell-state maintenance, necrosis prevention in engineered aggregates, orientation control, and scalable manufacturing considerations.
Translational Outlook
This program is positioned as translational regenerative medicine research, not a commercially available treatment. Clinical data remain internal and subject to appropriate regulatory pathways before any public therapeutic offering.
Derivative approaches—including growth-factor and conditioned-media research—may complement the core cell-therapy platform. Orion Biotech welcomes academic and clinical research partnerships aligned with rigorous scientific standards.